文献速递心境障碍

肿瘤坏死因子拮抗剂对高炎症抑郁症患者动机缺陷及相关皮质纹状体环路的随机机制验证试验

A randomized proof-of-mechanism trial of TNF antagonism for motivational deficits and related corticostriatal circuitry in depressed patients with high inflammation.
PubMed 文献 · Mol Psychiatry · 2024-09-17

该随机双盲安慰剂对照单剂量试验纳入42例C反应蛋白>3 mg/L的未用药重度抑郁症患者,比较英夫利西单抗5 mg/kg与安慰剂对努力型决策、自评问卷及事件相关功能磁共振神经反应的影响。结果显示,英夫利西单抗组较安慰剂组更愿意为奖励付出努力,努力选择增加与可溶性肿瘤坏死因子受体2型下降相关,且后者中介了药物条件与行为及神经影像指标的关系。

要点

  • 英夫利西单抗组较安慰剂组更愿意为奖励付出努力。
  • 努力选择增加与可溶性肿瘤坏死因子受体2型下降相关。
  • 可溶性肿瘤坏死因子受体2型变化中介了药物条件与行为及神经影像指标的关系。

核心结论

  • 数据支持对高炎症抑郁症患者使用抗炎治疗以改善努力型决策及相关脑环路。

研究设计与样本

  • 42例医学状况稳定、未用药且C反应蛋白>3 mg/L的重度抑郁症患者参与双盲、安慰剂对照、单剂量随机临床试验,比较英夫利西单抗5 mg/kg与安慰剂。
  • 在基线及输注后2周评估努力型决策任务行为表现、自评问卷及事件相关功能磁共振神经反应。

主要发现

  • 与安慰剂相比,接受英夫利西单抗的患者更愿意为奖励付出努力。
  • 努力选择增加与可溶性肿瘤坏死因子受体2型下降所反映的肿瘤坏死因子信号减弱相关。
  • 努力型决策及可溶性肿瘤坏死因子受体2型的变化与背内侧前额叶皮层、腹侧纹状体、壳核等活动变化及这些区域间功能连接变化相关。
  • 可溶性肿瘤坏死因子受体2型变化中介了药物条件与行为及神经影像指标的关系。
  • 自评快感缺失症状及努力折扣行为的变化与一个独立验证的、对金钱奖励敏感的全脑预测模型(神经特征)反应增强相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic, low-grade inflammation has been associated with motivational deficits in patients with major depression (MD). In turn, impaired motivation has been linked to poor quality of life across psychiatric disorders. We thus determined effects of the anti-inflammatory drug infliximab-a potent tumor necrosis factor (TNF) antagonist-on behavioral and neural measures of motivation in 42 medically stable, unmedicated MD patients with a C-reactive protein >3 mg/L. All patients underwent a double-blind, placebo-controlled, single-dose, randomized clinical trial with infliximab (5 mg/kg) versus placebo. Behavioral performance on an effort-based decision-making task, self-report questionnaires, and neural responses during event-related functional magnetic resonance imaging were assessed at baseline and 2 weeks following infusion. We found that relative to placebo, patients receiving infliximab were more willing to expend effort for rewards. Moreover, increase in effortful choices was associated with reduced TNF signaling as indexed by decreased soluble TNF receptor type 2 (sTNFR2). Changes in effort-based decision-making and sTNFR2 were also associated with changes in task-related activity in a network of brain areas, including dorsomedial prefrontal cortex (dmPFC), ventral striatum, and putamen, as well as the functional connectivity between these regions. Changes in sTNFR2 also mediated the relationships between drug condition and behavioral and neuroimaging measures. Finally, changes in self-reported anhedonia symptoms and effort-discounting behavior were associated with greater responses of an independently validated whole-brain predictive model (aka "neural signature") sensitive to monetary rewards. Taken together, these data support the use of anti-inflammatory treatment to improve effort-based decision-making and associated brain circuitry in depressed patients with high inflammation.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Treadway MT, Etuk SM, Cooper JA, et al. A randomized proof-of-mechanism trial of TNF antagonism for motivational deficits and related corticostriatal circuitry in depressed patients with high inflammation. Mol Psychiatry. 2024. PMID: 39289477. doi:10.1038/s41380-024-02751-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。